CGCN GROUP, LLC

Lobbying for FRESENIUS KABI USA, LLC · Healthcare company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Illinois · House · Senate · $30,000.00 income · posted Oct 20, 2025

Lobbying activity 4

Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.

Manufacturing

Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers.

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices.

Taxation/Internal Revenue Code

U.S. manufacturing incentives.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.